Enjoy complimentary customisation on priority with our Enterprise License!
The gastrointestinal stromal tumors therapeutics market size is forecast to increase by USD 1.02 billion at a CAGR of 6.01% between 2023 and 2028. The gastrointestinal stromal tumors (GIST) therapeutics market is witnessing significant growth due to several key factors. The global geriatric population is expanding, with individuals aged 65 and above being more susceptible to GIST, thereby driving market demand. Additionally, the advent of regenerative therapy for GIST, such as tyrosine kinase inhibitors (TKIs), is revolutionizing treatment approaches and offering improved patient outcomes. However, high treatment costs remain a major challenge for the market, as TKIs can be expensive and may lead to financial burden for patients. Despite this, the market is expected to continue its growth trajectory, fueled by the increasing prevalence of GIST and the development of innovative treatment options.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Route of Administration
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.